Jaguar Health Strengthens its Executive Team with a New Growth Strategy Appointee

Jaguar Health, Inc. announced Catherine Miller Collis as the new Senior Vice President of Growth Strategy. Collis brings over two decades of biopharmaceutical experience to Jaguar, aiming to advance the company's strategic initiatives in cancer and GI supportive care. Her immediate past role involved leading Jaguar's licensing agreement for the FDA-approved Gelclair®, a management gel for oral mucositis caused by cancer treatments.

Jaguar's CEO, Lisa Conte, emphasized Collis's extensive experience in commercial and business development, crucial for Jaguar's next phase, which includes the commercial launch of Gelclair®. The company plans to expand its product offerings to address unmet needs in supportive care for complex diseases like cancer.

In her statement, Collis highlighted the importance of providing supportive care products like Gelclair® that offer pain relief without numbing, thus enhancing quality of life for cancer patients. The company is also awaiting results from a Phase 3 trial of crofelemer for cancer therapy-related diarrhea, marking a significant foray into cancer-related supportive care.